Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07430501Not Yet Recruiting

Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatment, and Long-term Monitoring of Patients Across the Full Spectrum of Metabolic-associated Fatty Liver Disease (MAFLD).

Role: collaborator

NCT06624787Not ApplicableNot Yet Recruiting

Development Of A Rapid Diagnostic Test To Identify Crimean-Congo Haemorrhagic Fever At The Point-Of-Care

Role: collaborator

NCT04649775Not ApplicableTerminated

AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19

Role: collaborator

NCT00199979Phase 3Unknown

Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients

Role: lead

All 4 trials loaded